253 related articles for article (PubMed ID: 32019318)
1. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.
Bylo M; Farewell R; Coppenrath VA; Yogaratnam D
Ann Pharmacother; 2020 Aug; 54(8):788-794. PubMed ID: 32019318
[No Abstract] [Full Text] [Related]
2. Corticosteroids for the treatment of Duchenne muscular dystrophy.
Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
[TBL] [Abstract][Full Text] [Related]
5. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
[TBL] [Abstract][Full Text] [Related]
6. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
Singh A; Schaeffer EK; Reilly CW
J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
[TBL] [Abstract][Full Text] [Related]
7. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
Biggar WD; Skalsky A; McDonald CM
J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
[TBL] [Abstract][Full Text] [Related]
8. The impact of deflazacort on puberty in Duchenne muscular dystrophy.
Dooley JM; Bobbitt SA; Cummings EA
Pediatr Neurol; 2013 Oct; 49(4):292-3. PubMed ID: 23921283
[TBL] [Abstract][Full Text] [Related]
9. Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): A randomized, double-blind non-inferiority trial.
Reddy C; Patil AN; Suthar R; Sankhyan N; Sirari T; Kumar A; Bhattacharjee S; Saxena S; Saini AG; Sahu JK
Eur J Paediatr Neurol; 2022 May; 38():77-84. PubMed ID: 35500465
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid-Associated Demise of a Patient With Duchenne Muscular Dystrophy.
Brahmsteadt AE; Bach JR; Pishdad R; Cespedes L; Pierucci P
Am J Phys Med Rehabil; 2020 Dec; 99(12):e146-e148. PubMed ID: 32195738
[TBL] [Abstract][Full Text] [Related]
11. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
Lamb MM; West NA; Ouyang L; Yang M; Weitzenkamp D; James K; Ciafaloni E; Pandya S; DiGuiseppi C;
J Pediatr; 2016 Jun; 173():207-213.e3. PubMed ID: 27039228
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
Balaban B; Matthews DJ; Clayton GH; Carry T
Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of deflazacort and doxycycline: a potential pharmacotherapy for Duchenne muscular dystrophy.
Pereira JA; Marques MJ; Santo Neto H
Clin Exp Pharmacol Physiol; 2015 Jul; 42(7):788-94. PubMed ID: 25959722
[TBL] [Abstract][Full Text] [Related]
15. Myocarditis in Duchenne Muscular Dystrophy After Changing Steroids.
Abutaleb ARA; McNally EM; Khan SS; Anderson AS; Carr JC; Wilcox JE
JAMA Cardiol; 2018 Oct; 3(10):1006-1010. PubMed ID: 30167630
[TBL] [Abstract][Full Text] [Related]
16. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.
Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Hirtz D; Shieh PB; Straub V; Childs AM; Ciafaloni E; Butterfield RJ; Horrocks I; Spinty S; Flanigan KM; Kuntz NL; Baranello G; Roper H; Morrison L; Mah JK; Manzur AY; McDonald CM; Schara U; von der Hagen M; Barohn RJ; Campbell C; Darras BT; Finkel RS; Vita G; Hughes I; Mongini T; Pegoraro E; Wicklund M; Wilichowski E; Bryan Burnette W; Howard JF; McMillan HJ; Thangarajh M; Griggs RC
Contemp Clin Trials; 2017 Jul; 58():34-39. PubMed ID: 28450193
[TBL] [Abstract][Full Text] [Related]
17. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
Wong BL; Rybalsky I; Shellenbarger KC; Tian C; McMahon MA; Rutter MM; Sawnani H; Jefferies JL
J Pediatr; 2017 Mar; 182():296-303.e1. PubMed ID: 28043681
[TBL] [Abstract][Full Text] [Related]
20. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
